Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | June 18, 2026 | June 23, 2026 |
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Chief Executive Officer | March 04, 2026 | March 06, 2026 |
| Neuronetics, Inc.STIM · Entity 6248 | Director | May 25, 2023 | May 30, 2023 |
| TELA Bio, Inc.TELA · Entity 7381 | Director | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,805 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 10,402 · Balance 30,805 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.
MIMEDX GROUP, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 904,656 |
Reported balance
After 2026-03-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-04 · Grant · Acquired 371,094 · Balance 904,656 F1: Represents grant of restricted stock which vests fully on the third anniversary of the grant, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement. F2: Includes an aggregate of 4,032 shares acquired on July 31, 2025 and January 30, 2026 pursuant to the MiMedx Group, Inc. Employee Stock Purchase Plan. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2033-03-03 | Direct | 4,087,938 |
Reported balance
After 2026-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-04 · Grant · Acquired 310,574 · Balance 4,087,938 F3: The options granted to the reporting person shall vest 25% on each anniversary of the grant date, subject to the reporting person's continued employment as specified in the Nonqualified Stock Option Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock which vests fully on the third anniversary of the grant, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement.
F2: Includes an aggregate of 4,032 shares acquired on July 31, 2025 and January 30, 2026 pursuant to the MiMedx Group, Inc. Employee Stock Purchase Plan.
F3: The options granted to the reporting person shall vest 25% on each anniversary of the grant date, subject to the reporting person's continued employment as specified in the Nonqualified Stock Option Agreement.
Neuronetics, Inc.
Report date May 25, 2023 · Filed May 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,147 |
Reported balance
After 2023-05-25 transaction · row 1
1 source rowRow 1 · 2023-05-25 · Grant · Acquired 36,364 · Balance 43,147 F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
TELA Bio, Inc.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,827 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-14 · Purchase · Acquired 25,000 · Balance 54,827 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9899 to $1.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Row 2 · 2026-09-15 · Purchase · Acquired 50,000 · Balance 104,827 F2: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.01 to $1.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9899 to $1.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.01 to $1.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOTELEMETRY, INC.
Report date February 09, 2021 · Filed February 12, 2021
Section 16 reporting ended · disclosed 2021-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-02-09 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2020-12-28 · Gift · Disposed 1,400 · Balance 166,972 Row 2 · 2020-12-29 · Gift · Disposed 1,400 · Balance 165,572 Row 3 · 2021-02-03 · Gift · Disposed 1,400 · Balance 164,172 Row 4 · 2021-02-03 · Gift · Disposed 1,400 · Balance 162,772 Row 5 · 2021-02-09 · Disposition to issuer · Disposed 162,772 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of December 18, 2020, among the Company, Philips Holding USA Inc., a Delaware corporation, and Davies Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock was validly tendered for $72.00 per share in cash (the "Offer Price"), less any applicable withholding taxes. F2: Includes 49,542 restricted stock units that, pursuant to the Merger Agreement, were cancelled at the Effective Time of the Merger (both as defined in the Merger Agreement) and converted into the right to receive the Offer Price, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2021-03-04 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-02-09 · Disposition to issuer · Disposed 54,235 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2022-02-21 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-02-09 · Disposition to issuer · Disposed 313,232 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2023-02-19 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-02-09 · Disposition to issuer · Disposed 257,177 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.68 · Expires 2024-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-02-09 · Disposition to issuer · Disposed 104,468 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.36 · Expires 2025-02-16 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-02-09 · Disposition to issuer · Disposed 122,538 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.57 · Expires 2026-02-15 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-02-09 · Disposition to issuer · Disposed 94,752 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.65 · Expires 2027-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-02-09 · Disposition to issuer · Disposed 45,917 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.35 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-02-09 · Disposition to issuer · Disposed 49,604 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.22 · Expires 2030-02-17 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-02-09 · Disposition to issuer · Disposed 42,291 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-02-09 · Disposition to issuer · Disposed 20,834 · Balance 0 F4: Per the terms of the Merger Agreement, each performance stock unit ("PSU") that was outstanding as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash equal to the product of (i) the total number of shares of Company common stock subject to such PSU that would have vested if the applicable performance period ended immediately prior to the Effective Time (assuming that any applicable performance conditions were deemed to be achieved at the target performance level), multiplied by (ii) the Offer Price, less applicable withholding taxes. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-02-09 · Disposition to issuer · Disposed 10,946 · Balance 0 F4: Per the terms of the Merger Agreement, each performance stock unit ("PSU") that was outstanding as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash equal to the product of (i) the total number of shares of Company common stock subject to such PSU that would have vested if the applicable performance period ended immediately prior to the Effective Time (assuming that any applicable performance conditions were deemed to be achieved at the target performance level), multiplied by (ii) the Offer Price, less applicable withholding taxes. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-02-09 · Disposition to issuer · Disposed 17,762 · Balance 0 F4: Per the terms of the Merger Agreement, each performance stock unit ("PSU") that was outstanding as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash equal to the product of (i) the total number of shares of Company common stock subject to such PSU that would have vested if the applicable performance period ended immediately prior to the Effective Time (assuming that any applicable performance conditions were deemed to be achieved at the target performance level), multiplied by (ii) the Offer Price, less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the terms of the Agreement and Plan of Merger, dated as of December 18, 2020, among the Company, Philips Holding USA Inc., a Delaware corporation, and Davies Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock was validly tendered for $72.00 per share in cash (the "Offer Price"), less any applicable withholding taxes.
F2: Includes 49,542 restricted stock units that, pursuant to the Merger Agreement, were cancelled at the Effective Time of the Merger (both as defined in the Merger Agreement) and converted into the right to receive the Offer Price, less any applicable withholding taxes.
F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes.
F4: Per the terms of the Merger Agreement, each performance stock unit ("PSU") that was outstanding as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash equal to the product of (i) the total number of shares of Company common stock subject to such PSU that would have vested if the applicable performance period ended immediately prior to the Effective Time (assuming that any applicable performance conditions were deemed to be achieved at the target performance level), multiplied by (ii) the Offer Price, less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 65,787 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · derivative · entry 9 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 65,787 shares Expires 2020-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options vested in four equal annual installments which began on June 15, 2011. The options were fully exercisable as of June 15, 2014. Read SEC document |
| June 13, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 65,787 | $44.18 | $2,906,469.66 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · nonDerivative · entry 6 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,355 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $43.50 to $44.43, inclusive. Read SEC document |
| June 13, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 65,787 | $6.56 | $431,562.72 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · nonDerivative · entry 5 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 79,292 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · derivative · entry 8 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,787 Underlying: Common Stock · 79,292 shares Expires 2020-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options vested in four equal annual installments which began on June 15, 2011. The options were fully exercisable as of June 15, 2014. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 79,292 | $43.88 | $3,479,332.96 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · nonDerivative · entry 4 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,355 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $43.20 to $44.50, inclusive. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 79,292 | $6.56 | $520,155.52 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · nonDerivative · entry 3 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 54,921 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · derivative · entry 7 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,079 Underlying: Common Stock · 54,921 shares Expires 2020-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options vested in four equal annual installments which began on June 15, 2011. The options were fully exercisable as of June 15, 2014. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 54,921 | $43.45 | $2,386,317.45 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · nonDerivative · entry 2 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,355 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $43.00 to $44.40, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, and 4 to this Form 4. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 22:05 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 54,921 | $6.56 | $360,281.76 |
DisclosureSEC source: 0001574774-18-000044 · wf-form4_152892749195255.xml · nonDerivative · entry 1 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2018 Filed Feb 14, 2019 23:21 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001574774-19-000008 · wf-form5_155018647391315.xml · nonDerivative · entry 1 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,855 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 21:12 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Tax withholdingCommon Stock | 30,923 | $33.67 | $1,041,177.41 |
DisclosureSEC source: 0001574774-18-000006 · wf-form4_151924750434565.xml · nonDerivative · entry 1 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,355 F1 · shares: Represents shares withheld to cover taxes in connection with the reporting person's February 16, 2015, RSU Grant. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:22 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GrantStock Options (Right to Buy) · Derivative | 49,604 | $0.00 Strike: $33.35 | $0.00 |
DisclosureSEC source: 0001574774-18-000004 · wf-form4_151881611072675.xml · derivative · entry 2 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,604 Underlying: Common Stock · 49,604 shares Expires 2028-02-14 F2 · derivative.exercise_date: The options shall vest in equal amounts on each of the first four anniversaries of the grant date, provided that the option holder remains in continuous service through the applicable vesting date. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:22 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GrantCommon Stock | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001574774-18-000004 · wf-form4_151881611072675.xml · nonDerivative · entry 1 Capper Joseph H · CIK 0001456817 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,278 F1 · shares: Represents shares of the Issuer's common stock underlying restricted stock units (RSUs) awarded to the Reporting Person. The RSUs will vest in full on the third anniversary of the grant date, subject to accelerated vesting upon certain terminations of employment following certain corporate transactions involving the Issuer. The shares of common stock underlying the RSUs will be issued when the RSUs vest. Read SEC document |
| February 15, 2017 Filed Feb 15, 2017 23:32 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Tax withholdingCommon Stock | 28,485 | $24.65 | $702,155.25 |
DisclosureSEC source: 0001209191-17-011211 · doc4.xml · nonDerivative · entry 2 Capper Joseph H · CIK 0001456817 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,444 F2 · shares: Represents shares withheld to cover taxes in connection with the reporting person's February 14, 2014 RSU Grant. F3 · price: Closing price of the Company's common stock on February 14, 2017 Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 23:32 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GrantStock Options · Derivative | 45,917 | $0.00 Strike: $24.65 | $0.00 |
DisclosureSEC source: 0001209191-17-011211 · doc4.xml · derivative · entry 3 Capper Joseph H · CIK 0001456817 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,917 Underlying: Common Stock · 45,917 shares Expires 2027-02-14 F4 · derivative.exercise_date: The shares shall vest at the rate of 25% on December 31 and on each of the first, second, and third anniversaries of the Vesting Commencement Date, provided that the Option holder remains in Continuous Service through the applicable vesting date. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 23:32 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GrantCommon Stock | 27,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011211 · doc4.xml · nonDerivative · entry 1 Capper Joseph H · CIK 0001456817 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,929 F1 · shares: Represents shares of the Issuer's common stock underlying restricted stock units (RSUs) awarded to the Reporting Person. The RSUs will vest in full on the third anniversary of the grant date, subject to accelerated vesting upon certain terminations of employment following certain corporate transactions involving the Issuer. The shares of common stock underlying the RSUs will be issued when the RSUs vest. Read SEC document |
| September 13, 2016 Filed Sep 13, 2016 21:28 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 26,847 | $18.23 | $489,420.81 |
DisclosureSEC source: 0001209191-16-141209 · doc4.xml · nonDerivative · entry 1 Capper Joseph H · CIK 0001456817 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,838 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2016 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.66, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 12:37 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 13,632 | $18.10 | $246,739.20 |
DisclosureSEC source: 0001209191-16-140855 · doc4.xml · nonDerivative · entry 1 Capper Joseph H · CIK 0001456817 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,685 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2016 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.25, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 22:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 26,133 | $18.52 | $483,983.16 |
DisclosureSEC source: 0001104659-16-143557 · a4.xml · nonDerivative · entry 3 Capper Joseph H · CIK 0001456817 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,317 F4 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.31 to $18.63, inclusive. Read SEC document |
| September 06, 2016 Filed Sep 7, 2016 22:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 30,595 | $18.29 | $559,582.55 |
DisclosureSEC source: 0001104659-16-143557 · a4.xml · nonDerivative · entry 2 Capper Joseph H · CIK 0001456817 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,450 F3 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.90, inclusive. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 22:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 29,953 | $18.75 | $561,618.75 |
DisclosureSEC source: 0001104659-16-143557 · a4.xml · nonDerivative · entry 1 Capper Joseph H · CIK 0001456817 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,045 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.60 to $18.91, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.